Scribe Therapeutics grants 14,725 stock options

Scribe Therapeutics, Inc. reported that Dr. Behzad Aghazadeh and affiliated entities Avoro Capital Advisors LLC and Avoro Ventures LLC received a grant of 14,725 stock options to purchase Common Stock.

Rhea-AI Filing Summary

Scribe Therapeutics, Inc. reported that Dr. Behzad Aghazadeh and affiliated entities Avoro Capital Advisors LLC and Avoro Ventures LLC received a grant of 14,725 stock options to purchase Common Stock. The options carry a $15.00 exercise price and expire on July 22, 2036. They vest in three equal installments on July 23, 2027, July 23, 2028, and July 23, 2029, subject to Dr. Aghazadeh’s continued service. The reporting persons expressly disclaim beneficial ownership of the securities except to the extent of their pecuniary interest.

Insider Trade Summary

Grant/Award: 14,725 shares

Grant/Award 1 txn

Insider Aghazadeh Behzad, Avoro Capital Advisors LLC, Avoro Ventures LLC

Role Director | Director | Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1, F2, F3	14,725	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 14,725 contracts (Direct)

Footnotes (3)

1. F1. The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's ("Dr. Aghazadeh") provision of service to the Issuer on each vesting date.
2. F2. This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), and Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures," together with Dr. Aghazadeh and Avoro Capital Advisors, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.
3. F3. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Key Figures

Options granted: 14,725 shares Exercise price: $15.00 per share Expiration date: July 22, 2036 +1 more

4 metrics

Options granted 14,725 shares Stock Option (Right to Buy) grant reported as of July 23, 2026

Exercise price $15.00 per share Conversion or exercise price of granted stock options

Expiration date July 22, 2036 Expiration of the granted stock options

Vesting dates July 23, 2027; July 23, 2028; July 23, 2029 Options vest 1/3 on each listed vesting date

Key Terms

Stock Option (Right to Buy), beneficial owner, Section 16 of the Securities Exchange Act of 1934, directors by deputization

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

beneficial owner financial

"shall not be deemed an admission that any Reporting Person is the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

Section 16 of the Securities Exchange Act of 1934 regulatory

"for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended"

A provision of federal securities law that requires company insiders—directors, officers and large shareholders—to publicly report their stock holdings and trades and to surrender any “short-swing” profits from purchases and sales within a six-month window. It acts like a rule that forces leaders to announce their trades and prevents quick buy-sell windfalls, giving investors transparency into insider activity and reducing opportunities for unfair gain.

directors by deputization regulatory

"may be deemed directors by deputization of the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Scribe Therapeutics (SCTX) report for Dr. Behzad Aghazadeh?

Scribe Therapeutics reported a grant of 14,725 stock options to Dr. Behzad Aghazadeh and affiliated entities. These options relate to the company’s Common Stock and were reported as an acquisition-type derivative transaction.

What is the exercise price of the new SCTX stock options granted to Dr. Aghazadeh?

The granted stock options have an exercise price of $15.00 per share. This is the price at which the holder may purchase Scribe Therapeutics Common Stock upon exercise of the options, subject to vesting and other terms.

When do the Scribe Therapeutics (SCTX) options granted to Dr. Aghazadeh vest?

The options vest in three equal tranches of 1/3 of the total shares on July 23, 2027, July 23, 2028, and July 23, 2029, conditioned on Dr. Aghazadeh’s continued service to Scribe Therapeutics on each vesting date.

What is the expiration date of the SCTX options granted to Dr. Aghazadeh and affiliates?

The stock options granted to the reporting persons expire on July 22, 2036. After this expiration date, any unexercised portion of the option can no longer be used to purchase Scribe Therapeutics Common Stock.

How many SCTX derivative securities does Dr. Aghazadeh hold after this option grant?

Following the reported transaction, the filing shows 14,725 stock options held as a result of this grant. The reporting persons state they disclaim beneficial ownership except to the extent of any pecuniary interest.

Do Avoro Capital Advisors and Avoro Ventures have any special role at Scribe Therapeutics (SCTX)?

Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of Scribe Therapeutics because Dr. Aghazadeh, their controlling person, serves on Scribe’s board of directors, according to the filing’s remarks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/10/2026 - 04:00 PM Accepted by SEC EDGAR 07/27/2026 - 09:04 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aghazadeh Behzad

(Last) (First) (Middle)

C/O AVORO CAPITAL ADVISORS LLC

110 GREENE STREET, SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Scribe Therapeutics, Inc. [ SCTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15	07/23/2026		A		14,725		(1)	07/22/2036	Common Stock	14,725	$0	14,725	D(2)(3)

1. Name and Address of Reporting Person^*

Aghazadeh Behzad

(Last) (First) (Middle)

C/O AVORO CAPITAL ADVISORS LLC

110 GREENE STREET, SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

1. Name and Address of Reporting Person^*

Avoro Capital Advisors LLC

(Last) (First) (Middle)

110 GREENE STREET

SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

1. Name and Address of Reporting Person^*

Avoro Ventures LLC

(Last) (First) (Middle)

110 GREENE STREET, SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			See Remarks

Explanation of Responses:

1. The options will vest as to 1/3 of the total shares on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to Behzad Aghazadeh's ("Dr. Aghazadeh") provision of service to the Issuer on each vesting date.

2. This Form 4 is filed by Dr. Aghazadeh, Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), and Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures," together with Dr. Aghazadeh and Avoro Capital Advisors, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.

3. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Remarks:

Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.

	Avoro Capital Advisors LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer	07/27/2026
	Avoro Ventures LLC, by: /s/ Scott Epstein, its Chief Operating Officer & Chief Compliance Officer	07/27/2026
	/s/ Behzad Aghazadeh	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)